Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. We show 1 historical shares outstanding datapoints in our coverage of PCVX's shares outstanding history.
Understanding the changing numbers of PCVX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PCVX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PCVX by allowing them to research PCVX shares outstanding history
as well as any other stock in our coverage universe. |
Free PCVX Email Alerts:
Video: Shares Outstanding Importance
